Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot dosimetry and toxicity study of lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer
NL-OMON46596Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) and prostate adenocarcinoma, sponsored by Radboud University Medical Center. Primary endpoints: Dosimetry of lutetium-177-PSMA-617 and Toxicity with focus on organs at risk. Started Sep 2018; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on NL-OMON46596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46596.